Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
- PMID: 23117005
- DOI: 10.1016/S1470-2045(12)70388-1
Do low-grade and low-volume prostate cancers bear the hallmarks of malignancy?
Abstract
Prostate cancer is generally multifocal and consists of a dominant focus-measured by tumour volume and deemed the index lesion-and one or more separate, secondary tumour foci of smaller volume. Much laboratory and clinical evidence has shown that we need to rethink how we regard low-grade and low-volume prostate lesions. In this Personal View, we discuss why small, low-grade Gleason pattern prostate lesions, which are currently designated as prostate cancer, could be regarded as non-malignant. These lesions either do not meet the criteria of the hallmarks of cancer or robust evidence that they do so is absent, by contrast with large lesions with a high Gleason grade, which seem to cause most metastatic disease.
Copyright © 2012 Elsevier Ltd. All rights reserved.
Similar articles
-
Low-grade prostate cancer diverges early from high grade and metastatic disease.Cancer Sci. 2014 Aug;105(8):1079-85. doi: 10.1111/cas.12460. Cancer Sci. 2014. PMID: 24890684 Free PMC article.
-
Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma.Am J Surg Pathol. 2017 Apr;41(4):e1-e7. doi: 10.1097/PAS.0000000000000820. Am J Surg Pathol. 2017. PMID: 28177964
-
More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.Hell J Nucl Med. 2019 Jan-Apr;22(1):6-9. doi: 10.1967/s002449910952. Epub 2019 Mar 7. Hell J Nucl Med. 2019. PMID: 30843003
-
Gene expression pathways of high grade localized prostate cancer.Prostate. 2011 Oct 1;71(14):1568-77. doi: 10.1002/pros.21373. Epub 2011 Feb 25. Prostate. 2011. PMID: 21360566
-
Gleason Score 6 - Prostate Cancer or Benign Variant?Oncol Res Treat. 2015;38(12):629-32. doi: 10.1159/000441735. Epub 2015 Nov 12. Oncol Res Treat. 2015. PMID: 26633167 Review.
Cited by
-
Histological characteristics of the largest and secondary tumors in radical prostatectomy specimens and implications for focal therapy.Diagn Pathol. 2019 Jan 12;14(1):2. doi: 10.1186/s13000-019-0782-8. Diagn Pathol. 2019. PMID: 30636627 Free PMC article.
-
Prostate cancer treatment with Irreversible Electroporation (IRE): Safety, efficacy and clinical experience in 471 treatments.PLoS One. 2019 Apr 15;14(4):e0215093. doi: 10.1371/journal.pone.0215093. eCollection 2019. PLoS One. 2019. PMID: 30986263 Free PMC article.
-
A multi-centre prospective development study evaluating focal therapy using high intensity focused ultrasound for localised prostate cancer: The INDEX study.Contemp Clin Trials. 2013 Sep;36(1):68-80. doi: 10.1016/j.cct.2013.06.005. Epub 2013 Jun 14. Contemp Clin Trials. 2013. PMID: 23774040 Free PMC article.
-
Role of focal salvage ablative therapy in localised radiorecurrent prostate cancer.World J Urol. 2013 Dec;31(6):1361-8. doi: 10.1007/s00345-013-1100-9. World J Urol. 2013. PMID: 24121817 Review.
-
Does true Gleason pattern 3 merit its cancer descriptor?Nat Rev Urol. 2016 Sep;13(9):541-8. doi: 10.1038/nrurol.2016.141. Epub 2016 Aug 17. Nat Rev Urol. 2016. PMID: 27530265 Review.
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical